Drostanolone Enanthate 200 mg/ml
Drostanolone Enanthate 200 mg/ml by Swiss Remedies is a long-acting DHT-derived anabolic steroid supplied in oil-based 1 ml ampoules. Non-aromatisable and historically investigated in oncology, it is now primarily used in laboratory research on androgen receptor signalling, metabolism and anti-doping detection. For research use only.
€ 69.00
Beskrivelse
Drostanolone Enanthate 200 mg/ml — Swiss Remedies
Brand: Swiss Remedies
Category: Injectable AAS · DHT-derived anabolic steroid
Content: 200 mg/ml drostanolone enanthate
Packaging: 10 × 1 ml ampoules (total 2,000 mg)
Origin: Switzerland
Price: €69
Research Notice: Laboratory, forensic or educational research only. Not for human or veterinary use.
🧪 Product Overview
Drostanolone Enanthate is the long-acting ester of drostanolone — a
dihydrotestosterone (DHT)–derived anabolic steroid that does not aromatise to estrogen.
The enanthate ester increases lipophilicity and produces a sustained intramuscular depot release.
Historically, drostanolone was clinically investigated for advanced breast cancer due to its
androgenic and anti-estrogenic effects. Today, it is globally classified as a
performance-enhancing drug and appears on the WADA S1 list of prohibited anabolic agents.
This listing is provided exclusively for research on androgen receptor signalling, AAS metabolism,
toxicology and anti-doping detection methods.
🔬 Key Research Highlights
DHT-derived structure:
Non-aromatisable → no conversion to estrogen, supporting research into pure androgenic signalling.
Strong AR agonist:
Binds the androgen receptor with high affinity → regulates protein synthesis, nitrogen balance and anabolic pathways.
Enanthate ester behaviour:
Prolonged release from injection site → suitable for long-acting androgen exposure models.
Oncology context:
Investigated historically for anti-estrogenic activity in breast cancer research.
Doping-relevance:
Prohibited anabolic agent (WADA S1); extensively studied in anti-doping detection science.
🧬 Mechanism of Action
- AR activation: Promotes transcription of genes for protein synthesis & nitrogen retention
- DHT-based profile: No aromatisation → research into androgen-only signalling effects
- Depot release: Enanthate ester prolongs systemic nandrogen exposure
- Anti-estrogenic action in breast tissue: Historical oncology interest
📊 Technical Specification Table
| Field | Data |
|---|---|
| Active substance | Drostanolone (as Drostanolone Enanthate) |
| Chemical class | Anabolic-androgenic steroid · 5α-reduced DHT derivative |
| Molecular formula | C20H32O2 (drostanolone base) |
| Molecular weight | ≈ 304.5 g/mol (base) |
| Aromatisation | Does not aromatise to estrogen |
| Historical medical use | Advanced breast cancer (discontinued in many regions) |
| Doping status | Prohibited anabolic agent (WADA S1) |
| Route (research context) | Intramuscular injection (oil-based) |
| Legal status | Controlled substance in many jurisdictions |
📚 Research Applications
- Androgen receptor signalling & transcription studies
- Comparative anabolic vs. androgenic profiling
- AAS metabolism & toxicology studies
- Anti-doping detection R&D (urine/blood identification)
- Comparison with testosterone, nandrolone & other AAS
⚠️ Side Effects / Risks (Class-Based)
- Androgenic effects: acne, oily skin, accelerated hair loss
- Endocrine suppression: reduced testosterone, fertility impact
- Virilisation in female subjects (deepened voice, hair changes)
- Changes in HDL/LDL and cardiovascular strain
- Potential hepatic stress at high or prolonged exposure
- Mood changes or irritability noted in AAS misuse reports
🧯 Compliance & Legal Notice
Drostanolone and its esters are banned at all times in sport by WADA and national anti-doping bodies.
Controlled substance in many jurisdictions; unauthorised possession may be illegal.
FOR RESEARCH USE ONLY. Not for human or animal use. Not a dietary supplement or bodybuilding product.
Researchers must follow institutional SOPs and regulatory requirements for handling anabolic steroids.
There are no reviews yet.
